Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

InMode reports Q3 revenue of $130.2M, revises guidance amid challenges

InMode faced challenges from macroeconomic headwinds, impacting international sales and necessitating a revision of full-year guidance.
Despite these challenges, the company demonstrated strong operational performance with high gross margins and strategic management changes.
Opportunities lie in new platform adoption, market realignment, and leveraging the strong cash position for future growth.
Overall, InMode remains well-positioned to navigate challenges and capitalize on opportunities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

YOKNEAM, Israel, July 28, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2021.

InMode Reports Record Second Quarter 2021 Financial Results: Quarterly Revenues of $87.3 Million Represent 184% Year Over Year Growth

InMode (INMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

InMode (INMD) Soars 12.5%: Is Further Upside Left in the Stock?

The company forecasts sunny skies for its highly in-demand business.

Why InMode Stock Shot Nearly 13% Higher on Monday

YOKNEAM, Israel, July 12, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq:  INMD ), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2021 before the Nasdaq market opens on Wednesday, July 28, 2021.

InMode Expects Record Second Quarter 2021 Revenue Between $86.5M-$87.0M, Increasing Full Year 2021 Revenue Guidance to $305-$315M

Growing demand for non-invasive and minimally invasive aesthetic treatments from patients has led physicians to increase orders for devices that make these procedures possible. INMD is a big beneficiary of this trend in the U.S. and internationally. It's doubled revenues between 2018 and 2020 selling devices to physicians while remaining profitable and debt free.

InMode: Multi-Year Uptrend Is Far From Over Despite Valuation Concerns

YOKNEAM, Israel, May 27, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will present at the Jefferies Virtual Healthcare Conference on June 4 th at 10:30 a.m.

InMode to Present at the Jefferies Virtual Healthcare Conference

Bruker

IDEXX Laboratories

Discovering new insights into Covid-19, particularly 'long Covid', InMode and Idexx peer Bruker continues to test new buy point. The post InMode, Idexx Peer Bruker Tests Buy Zone With New Insights Into 'Long Covid' appeared first on Investor's Business Daily.

InMode, Idexx Peer Bruker Tests Buy Zone With New Insights Into 'Long Covid'

Alteryx

DoorDash

MaxLinear

Verra Mobility Corp

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like DoorDash & Verra Mobility

Wall Street's best-performing analysts say investors should keep buying these stocks

InMode has produced excellent financial results since listing in 2019.

InMode: A Profitable Growth Story With Lots Of Potential

YOKNEAM, Israel, May 13, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that management will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Wednesday, May 26.

InMode to Present at the UBS Global Healthcare Virtual Conference

InMode is a leader in the medical aesthetic devices industry and blows competitors out of the water when comparing financial metrics.

InMode: Still A Multi-Bagger Stock In The Making, Still Worth Buying. Here's Why

InMode Ltd (INMD) CEO Moshe Mizrahy on Q1 2021 Results - Earnings Call Transcript

Builders FirstSource

Deckers Outdoor

Shareholders of Builders FirstSource Inc (BLDR, Financial), Deckers Outdoor Corp (DECK, Financial) and InMode Ltd (INMD, Financial) saw the value of their assets increase significantly in recent years, outperforming the S&P 500 Index. The share price of the benchmark index for the U.S. market ($4,164.66 as of May 4) has gained 47% over the past year, 56% over the past three years and 102% over the past five years through May 4.

A Trio of Strong Performers to Consider

YOKNEAM, Israel, May 5, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced consolidated financial results for its first quarter ended March 31, 2021.

InMode Reports First Quarter 2021 Financial Results: Quarterly Revenues of $65.5 Million Represent 62% Year over Year Growth. GAAP Earnings per Share of $0.63, 320% Year over Year Growth

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have continued to contribute to the company's Q1 top line.

InMode (INMD) to Report Q1 Earnings: What's in the Offing?

YOKNEAM, Israel, April 12, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter 2021 before the Nasdaq market opens on Wednesday, May 5, 2021.

InMode Expects First Quarter 2021 Revenue Between $65.0-$65.4M, Non-GAAP Earnings per Diluted Share Between $0.65-$0.67

YOKNEAM, Israel, March 30, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced Mr.

InMode to Present at the Needham 20th Annual Virtual Healthcare Conference

Virgin Galactic

StoneCo

C3.ai

Carrier Global

Expedia

Texas Pacific Land Trust

TripAdvisor

trivago

TS Innovation Acquisitions Corp.

Twitter

Upstart Holdings

Westwater Resources

Every Friday, at 3 p.m. ET, Ritholtz Wealth Management CEO Josh Brown and Benzinga CEO Jason Raznick host "The Boiler Room," a Clubhouse audio chat where listeners can pitch their favorite stock.

The 'Boiler Room' Stock Pitch Recap: Texas Pacific Land Corp, StoneCo, Virgin Galactic And More

Bioanalytical Systems

Semler Scientific

MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.

Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy

Founder-owners have demonstrated a strong track record of growth and profitability. The company's pristine balance sheet affords new pathways for growth and share repurchases.

InMode: Fast Growing Small Cap With Consistent Outperformance

YOKNEAM, Israel, March 16, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, has filed a complaint with the United States International Trade Commission ("ITC") alleging ILOODA's SecretRF fractional radio frequency ("RF") microneedling system, distributed in the United States by Cutera, Inc., infringes U.S. Patent No.

InMode Files ITC Complaint Against ILOODA and its U.S. Distributor, Cutera

Generac Holdings

Horizon Pharma

SVB Financial Group

Williams-Sonoma

Those looking for growth stocks to watch are always trying to discover top stocks making bullish moves amid rising profit estimates. Here are some ideas.

Screen Of The Day: These Growth Stocks Make Bullish Moves Amid Soaring Profits

InMode also held up above its fast-climbing 50-day moving average, a good sign for now. The post Growth Stocks Take A Shellacking; Is It Time To Lock In Profits In InMode, 360 DigiTech?

Growth Stocks Take A Shellacking; Is It Time To Lock In Profits In InMode, 360 DigiTech?

InMode (INMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will InMode (INMD) Gain on Rising Earnings Estimates?

InMode (INMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

News for Inmode Ltd Stock (INMD)